Urinary iron excretion induced by intravenous infusion of deferoxamine in ß-thalassemia homozygous patients

Página do item simplificado
dc.contributor.authorBoturão-Neto, Edmir [UNIFESP]
dc.contributor.authorMarcopito, Luiz Francisco [UNIFESP]
dc.contributor.authorZago, M.a.
dc.contributor.institutionUniversidade de São Paulo (USP)
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.date.accessioned2015-06-14T13:29:49Z
dc.date.available2015-06-14T13:29:49Z
dc.date.issued2002-11-01
dc.description.abstractThe purpose of the present study was to identify noninvasive methods to evaluate the severity of iron overload in transfusion-dependent ß-thalassemia and the efficiency of intensive intravenous therapy as an additional tool for the treatment of iron-overloaded patients. Iron overload was evaluated for 26 ß-thalassemia homozygous patients, and 14 of them were submitted to intensive chelation therapy with high doses of intravenous deferoxamine (DF). Patients were classified into six groups of increasing clinical severity and were divided into compliant and non-compliant patients depending on their adherence to chronic chelation treatment. Several methods were used as indicators of iron overload. Total gain of transfusion iron, plasma ferritin, and urinary iron excretion in response to 20 to 60 mg/day subcutaneous DF for 8 to 12 h daily are useful to identify iron overload; however, urinary iron excretion in response to 9 g intravenous DF over 24 h and the increase of urinary iron excretion induced by high doses of the chelator are more reliable to identify different degrees of iron overload because of their correlation with the clinical grades of secondary hemochromatosis and the significant differences observed between the groups of compliant and non-compliant patients. Finally, the use of 3-9 g intravenous DF for 6-12 days led to a urinary iron excretion corresponding to 4.1 to 22.4% of the annual transfusion iron gain. Therefore, continuous intravenous DF at high doses may be an additional treatment for these patients, as a complement to the regular subcutaneous infusion at home, but requires individual planning and close monitoring of adverse reactions.en
dc.description.affiliationUniversidade de São Paulo, and Banco de Sangue Regional (Hemocentro) Faculdade de Medicina de Ribeirão Preto Departamento de Clínica Médica
dc.description.affiliationUniversidade Federal de São Paulo (UNIFESP) Departamento de Medicina Preventiva
dc.description.affiliationUnifespUNIFESP, Depto. de Medicina Preventiva
dc.description.sourceSciELO
dc.format.extent1319-1328
dc.identifierhttp://dx.doi.org/10.1590/S0100-879X2002001100009
dc.identifier.citationBrazilian Journal of Medical and Biological Research. Associação Brasileira de Divulgação Científica, v. 35, n. 11, p. 1319-1328, 2002.
dc.identifier.doi10.1590/S0100-879X2002001100009
dc.identifier.fileS0100-879X2002001100009.pdf
dc.identifier.issn0100-879X
dc.identifier.scieloS0100-879X2002001100009
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/1543
dc.identifier.wosWOS:000179717100009
dc.language.isoeng
dc.publisherAssociação Brasileira de Divulgação Científica
dc.relation.ispartofBrazilian Journal of Medical and Biological Research
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectß-Thalassemiaen
dc.subjectIron overloaden
dc.subjectDeferoxamineen
dc.subjectIron excretionen
dc.titleUrinary iron excretion induced by intravenous infusion of deferoxamine in ß-thalassemia homozygous patientsen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Pacote Original
Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
S0100-879X2002001100009.pdf
Tamanho:
491.35 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
Coleções
EPM - Artigos